ASCO Highlights: Idelalisib, obinutuzumab in CLL

Tweet

Leukemia, Myelodysplasia, and Transplantation

Final results of a phase I study of idelalisib (GS‑1101) a selective inhibitor of PI3Kδ, in patients with relapsed or refractory CLL

Jennifer R. Brown, MD, PhD

Idelalisib shows substantial clinical activity and a favorable safety profile in heavily pretreated, refractory and highErisk pts with chronic lymphocytic leukemia. Phase III trials with idelalisib in combination with rituximab or bendamustine/rituximab are ongoing.

More on idelalisib:Dr. Jennifer Brown Discusses Single Agents in CLL

Obinutuzumab (GA101) plus chlorambucil (Clb) or rituximab (R) plus Clb versus Clb alone in patients with chronic lymphocytic leukemia (CLL) and preexisting medical conditions (comorbidities): Final stage 1 results of the CLL11 (BO21004) phase III trial

Valentin Goede

Chemoimmunotherapy with GA101 + chlorambucil or rituximab + chlorambucil significantly prolongs PFS vs chlorambucil alone. The results demonstrate that GA101 + chlorambucil and rituximab + chlorambucil are very active in chronic lymphocytic leukemia and superior treament options in this population. GA101 + chlorambucil vs rituximab + chlorambucil will be compared in stage 2 analysis with more follow-up available.

Lung Cancer

START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer

Charles A. Butts, MD, FRCPC

L-BLP25 maintenance therapy in stage III NSCLC was well tolerated, but did not significantly prolong overall survival. Sensitivity analyses showed a smaller treatment effect due to the clinical hold, suggesting that longer uninterrupted treatment with L-BLP25 is required. Clinically meaningful prolongation of overall survival was observed in the predefined subgroup of pts with primary concurrent chemoradiotherapy.

Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small cell lung cancer: A randomized, placebo controlled phase II study CALGB 30504 (ALLIANCE)

Neal Ready, MD, PhD

The primary objective was met showing improved PFS for maintenance sunitinib. There was a non-significant trend toward improved OS despite crossover design. Sunitinib was well tolerated. Further study of sunitinib after chemotherapy for SCLC is justified.

<<<

View all coverage from the 2013 ASCO Meeting